$Armata Pharmaceuticals(ARMP.US)$Armata has shown a rapid enrollment rate in the Phase 2a portion of the diSArm study, which tests AP-SA02 as a potential treatment for Staphylococcus aureus bacteremia. Furthermore, the company is making strides in the Phase 2 Tailwind study of AP-PA02 in non-cystic fibrosis bronchiectasis (NCFB) patients with Pseudomonas aeruginosa lung infections. The second reason for is Armata’s diligence in preparing for future studies. The company i...
Armata Pharmaceuticals股票討論區
The second reason for is Armata’s diligence in preparing for future studies. The company i...
$NN Inc(NNBR.US)$ AH up 12% may look for lower entry or risk management will help
$Armata Pharmaceuticals(ARMP.US)$
$阿瑪琳(AMRN.US)$
$Moderna(MRNA.US)$
$美國原油基金ETF(USO.US)$
$錫安石油和天然氣(ZN.US)$
$Athersys Inc(ATHX.US)$
$TARONIS TECHNOLOGIES INC(TRNX.US)$
暫無評論